Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
GeneCentric Therapeutics Announces Commercial Availability of PurIST℠ Test for Pancreatic Cancer
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that […]
CardioRenal receives FDA Breakthrough Device Designation for TENOR
CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), […]
Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial
Cumulus Neuroscience, a global digital health company focused on advancing neuroscience clinical trials and patient […]
Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection Applications for Translational Research and Precision Therapeutics
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced breakthrough improvements […]
Ostentus Therapeutics and City of Hope to Continue Studies of Novel OST Natural Products for Treatment of Leukemia and Other Cancers
Ostentus Therapeutics announced today that it has entered into a second Sponsored Research Agreement with […]
Historic Milestone: UK Patients Receive First CannEpil® Delivery through 'I AM Billy Foundation' and GMC Specialist Register
MGC Pharmaceuticals, a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its […]
CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia
CANbridge Pharmaceuticals, a leading China-based global biopharmaceutical company committed to the research, development and commercialization […]
Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer
Hinge Bio, a privately-held biotechnology company, today announced that Juha Punnonen, M.D., Ph.D. has joined […]
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Pfizer has announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has […]
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
Inhibrx, a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more